289.08MMarket Cap-4.06P/E (TTM)
22.250High18.800Low445.05KVolume21.490Open21.090Pre Close9.00MTurnover4.43%Turnover RatioLossP/E (Static)15.00MShares31.01052wk High3.45P/B193.42MFloat Cap6.61252wk Low--Dividend TTM10.04MShs Float188.800Historical High--Div YieldTTM16.36%Amplitude3.862Historical Low20.218Avg Price1Lot Size
Jasper Therapeutics Stock Forum
Jasper Therapeutics Reports Positive Data from SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria
14 of 15 participants enrolled achieved a clinical response
10 of 12 participants in the 120mg cohort achieved a complete response
No serious adverse events; no grade 3 or higher adverse events reported
Initial data from BEACON study expected week of January 6th, 2025, including 180mg Q8W cohort
Company to host conference call and webinar today at 8:00 ...
Microsoft $Microsoft (MSFT.US)$ (office currently has nearly 400 million users, OficARPU increases after the acquisition of OpenA and Azurez-related...
No comment yet